Acorda Has Suffered 2 Setbacks, Both Of Which Can Be Dealt With [Seeking Alpha]
Acorda Therapeutics, Inc. (ACOR)
Last acorda therapeutics, inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acorda.com/investors
Company Research
Source: Seeking Alpha
Summary Acorda Therapeutics receives notice that its inhaled Parkinson's treatment Inbrija has been pushed back to January 5, 2019. Another setback came about when Acorda lost a court battle over 4 patents for the company's multiple sclerosis strengthening drug Ampyra. If Inbrija is ultimately approved by the FDA it could generate up to $800 million in peak sales. In the most recent second-quarter earnings it was noted that Ampyra generated $153.3 million in sales and Acorda stated that it is prepared for upcoming generic versions of the drug. The previous week was a rough one for Acorda Therapeutics ( ACOR ) but I believe that it will recover. The first issue was that the FDA pushed back the PDUFA date for its inhaled therapy for Parkinson's disease by many months. The second problem lies with not being able to uphold patents with its multiple sclerosis drug Ampyra. However, I believe there are certain paths forward. For these reasons, I believe that Acorda Therapeut
Show less
Read more
Impact Snapshot
Event Time:
ACOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACOR alerts
High impacting Acorda Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACOR
News
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024Business Wire
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- Klick Health Launches First AI Social Media Comment Moderator for Life Sciences Industry [Yahoo! Finance]Yahoo! Finance
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
ACOR
Sec Filings
- 3/13/24 - Form 8-K
- 1/11/24 - Form 8-K
- ACOR's page on the SEC website